Wird geladen...
Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials
Tumours with sensitizing mutations in the EGFR gene constitute a distinct molecular subgroup of non-small-cell lung cancers (nsclcs) that benefit from precision medicine. First- and second-generation epidermal growth factor receptor (egfr) tyrosine kinase inhibitors (tkis) are recommended as upfront...
Gespeichert in:
| Veröffentlicht in: | Curr Oncol |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Multimed Inc.
2018
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6001758/ https://ncbi.nlm.nih.gov/pubmed/29910645 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.25.3796 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|